71-LB: Tirzepatide Reduces the Predicted Risk of Developing Type 2 Diabetes—SURMOUNT-1 Post Hoc Analysis by Prediabetes Status

Background: This study assessed the effect of tirzepatide (TZP) on the 10-year risk of developing type 2 diabetes (T2D) in people with overweight or obesity with and without prediabetes.

Methods: The Cardiometabolic Disease Staging model was applied to the SURMOUNT-1 trial to derive T2D risk scores at baseline, 24, and 72 weeks. Mean change from baseline to week 72 was derived for participants with and without prediabetes at baseline.

Results: Age, sex, BMI, and other cardiometabolic factors were significantly different between participants with (n=987) and without prediabetes (n=1552). Mean baseline 10-year diabetes risk scores of participants with and without prediabetes were 29-32% and 19-20%, respectively, and did not differ by treatment group. Mean absolute reductions from baseline in the risk score at week 72 for TZP 5/10/15 mg were greater in participants with prediabetes (16-20%) vs those without prediabetes (10-11%), and both were greater than PBO. Mean change in 10-year risk vs PBO in the TZP 5/10/15 mg groups was -13%, -17%, and -18% respectively in those with prediabetes and -11%, -12%, and -12% in those without; the reduction was greater in participants with prediabetes (interaction p<0.001). Conclusion: TZP significantly reduced the predicted risk of developing T2D compared to PBO regardless of prediabetes status. Risk reduction was greater in participants with prediabetes.